Total: $570.9M

Company
(Symbol)^#
(M)

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details (Date)^@

Acacia
Research-
CombiMatrix
(CBMX)

Private placement of stock and warrants

6.4S and 1.6W

$10.5

The shares were sold in a registered direct offering at $1.65 each; the five-year warrants are exercisable at $2.40 per share; Piper Jaffray & Co. was placement agent (9/16)

Advanced Cell
Technology
Inc. (OTC BB:
ACTC)

Private placement of convertible notes and warrants

N/A and 4.84W

$17.75M

The three-year notes are convertible into 9.67M shares of stock at $2.30 per share; the five-year warrants are exercisable at $2.53 per share; T.R. Winston & Co. was placement agent (9/16)

Ascentia
Biomedical
Corp. (PK:ASCE)

Private placement of convertible notes

N/A

$1

Winsted Holdings Inc. committed to purchase up to $1M in a series of convertible notes; terms were not disclosed (9/14)

Emisphere
Technologies
Inc. (EMIS)

Loan

N/A

$15

The senior secured loan was provided by MHR Fund Management LLC; the loan may be exchanged for a note convertible into stock (9/26)

Genaera Corp.
(GENR)

Private placement of stock and warrants

11.4S and 3.42W

$24.5

The registered stock was purchased at $2.15 per share; the warrants are exercisable at $3.15 per share; RBC Capital Markets Corp. was lead placement agent and Fortis Securities LLC was co-agent (9/12)

GenVec Inc.
(GNVC)

Private placement of stock

7.65S

$15.3

Shares in the registered direct offering were sold at $2 each; SG Cowen & Co. LLC was placement agent (9/21)

Geron Corp.
(GERN)

Warrant exercise

2S

$18

Merck & Co. Inc. exercised a warrant to purchase 2M shares of stock at $9 each; the deal was made concurrent with Geron's public offering of 6M shares priced at $9 each (9/16)

Inflazyme
Pharmaceuticals
Inc. (Canada;
TSE:IZP)

Restructuring of subsidiary

N/A

C$3.4
(US$2.9)

Inflazyme realized C$3.4M from the sale of convertible debentures by the subsidiary; a put agreement to sell its holdings in the subsidiary could bring Inflazyme another C$2.5M by March 15, 2006 (9/20)

Lipid
Sciences Inc.
(LIPD)

Private
placement of
stock and
warrants

2.43S and
1.94W

$7.2

The shares were sold at $2.98 each; 62.5 of the warrants are exercisable at $3.73 per share; the remaining warrants are exercisable for five years at $4.20 per share; A.G. Edwards was placement agent (9/29)

Memory
Pharmaceuticals
Corp. (MEMY)

Private
placement of
stock and warrants

16.1S and
5.6W

$30.6

The shares were sold at $1.90 each; the warrants
are exercisable at $2.22 per share (9/21)

Nanogen
Inc. (NGEN)

Private
placement of
stock and
warrants

6.8S and
1W

$20

Institutional investors purchased the shares at $2.94 each; the five-year warrants are exercisable at $4 per share; Seven Hills Partners LLC was lead placement agent; Stonegate Securities Inc. was co- placement agent (9/28)

Nektar
Therapeutics
(NKTR)

Private placement of stock

0.455S

$8

Mainfield Enterprises Inc., which invested $24M in Nektar in August, exercised its option from that deal to acquire an additional 454,803 shares (9/8)

Nektar
Therapeutics
(NKTR)

Private placement of convertible notes

N/A

$315

The 3.25 subordinated notes due 2012 are convertible into common stock at $21.52 per share; totals include the purchase of $40M in notes per the investors' option (9/22)

Optigenex Inc.
(OTC BB:OPGX)

Private placement of notes and warrants

N/A and 0.625

$4

The three-year, 8 notes are convertible into stock at the lower of $3.20 or 40 of a 20-day trading average; terms of the five-year warrants were not disclosed (9/7)

Spectrum
Pharmaceuticals
Inc. (SPPI)

Private placement of stock and warrants

8S and 4W

$42

The shares were sold from a shelf registration at $5.25 each; the six-year warrants are exercisable at $6.62 per share; Rodman and Renshaw LLC was placement agent (9/15)

Transgenomic
Inc. (TBIO)

Private placement of stock and warrants

15S and 6W

$15.15

Institutional investors led by Lehman Brothers bought the shares at $1.01 each; the warrants are exercisable at $1.20 per share (9/23)

VaxGen Inc.
(PK:VXGN)

Sale of interest in subsidiary

N/A

$15

A group of South Korean investors purchased part of VaxGen's stake in Celltrion Inc., reducing VaxGen's stake in the South Korean manufacturing operation to 22.2 from 26.9(9/21)

York Pharma
plc (UK;
AIM:YRK)

Private placement of stock

4.717S

£5 (US$9)

The shares were placed at 106 pence each with institutional and other investors (9/16)

Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to repay or replace existing debt.

^# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Investment Market; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange.